Literature DB >> 15561826

Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.

Fernando Alcaide1, Laura Calatayud, Miguel Santín, Rogelio Martín.   

Abstract

Mycobacterium kansasii is one of the most pathogenic and frequent nontuberculous mycobacteria isolated from humans. Patients with adverse drug reactions, resistant isolates, or suboptimal response require alternative treatment regimens. One hundred forty-eight consecutive clinical isolates of M. kansasii were tested for antimicrobial susceptibilities by the BACTEC 460 system (NCCLS) with two different inoculation protocols, one conventional and one alternative. In the alternative protocol, the inoculum 12B vial was incubated until the growth index was between 250 and 500. Four conventional antimycobacterial drugs (isoniazid, rifampin, streptomycin, and ethambutol) were studied with standard critical concentrations. The in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, and moxifloxacin were determined by measuring radiometric MICs. All isolates tested were identified as M. kansasii genotype I and were resistant to isoniazid at a concentration of 0.4 mug/ml. One hundred twenty isolates (81.1%) were inhibited by 1 microg of isoniazid per ml. A high level of resistance to isoniazid (>10 microg/ml) was observed in six isolates (4.1%). Only five strains (3.4%) were resistant to rifampin (>1 microg/ml). All isolates studied were susceptible to streptomycin and ethambutol. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: linezolid, 1 (range, < or =0.25 to 2); telithromycin, >16 (range, 4 to >16); clarithromycin, 0.5 (range, < or =0.03 to 1); levofloxacin, 0.12 (range, 0.12 to 0.25); and moxifloxacin, 0.06 (range, < or =0.06 to 0.12). The susceptibility testing results with both inoculation protocols showed perfect correlation. In conclusion, all M. kansasii isolates showed decreased susceptibility to isoniazid, but resistance to rifampin was infrequent. Quinolones, especially moxifloxacin, were the most active antimicrobial agents tested, followed by clarithromycin. Linezolid also showed good activity against these microorganisms, but telithromycin's in vitro activity was poor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561826      PMCID: PMC529232          DOI: 10.1128/AAC.48.12.4562-4565.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience.

Authors:  M Lillo; S Orengo; P Cernoch; R L Harris
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital.

Authors:  M J Bittner; E A Horowitz; T J Safranek; L C Preheim
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

3.  Mycobacterium kansasii diffuse pulmonary infection in a patient with acquired immune deficiency syndrome. Successful therapy with an antituberculous regimen.

Authors:  M A Jacobson; W M Isenberg
Journal:  Am J Clin Pathol       Date:  1989-02       Impact factor: 2.493

4.  Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

5.  Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods.

Authors:  C N Lee; L B Heifets
Journal:  Am Rev Respir Dis       Date:  1987-08

Review 6.  Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1.

Authors:  R S Witzig; B A Fazal; R M Mera; D M Mushatt; P M Dejace; D L Greer; N E Hyslop
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

7.  Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.

Authors:  C H Ahn; R J Wallace; L C Steele; D T Murphy
Journal:  Am Rev Respir Dis       Date:  1987-01

8.  In-vitro activity of quinolones and macrolides against mycobacteria.

Authors:  W W Yew; L J Piddock; M S Li; D Lyon; C Y Chan; A F Cheng
Journal:  J Antimicrob Chemother       Date:  1994-09       Impact factor: 5.790

9.  Rifampin-resistant Mycobacterium kansasii.

Authors:  R J Wallace; D Dunbar; B A Brown; G Onyi; R Dunlap; C H Ahn; D T Murphy
Journal:  Clin Infect Dis       Date:  1994-05       Impact factor: 9.079

10.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.

Authors:  B A Brown; R J Wallace; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  11 in total

1.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Authors:  Zofia Bakuła; Magdalena Modrzejewska; Lian Pennings; Małgorzata Proboszcz; Aleksandra Safianowska; Jacek Bielecki; Jakko van Ingen; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.

Authors:  Carmen A Molina-Torres; Jorge Ocampo-Candiani; Adrian Rendón; Michael J Pucci; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

3.  Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis.

Authors:  A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-25       Impact factor: 3.267

Review 4.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

Review 5.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

6.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

7.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

8.  Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.

Authors:  Vitalii Litvinov; Marina Makarova; Ksenia Galkina; Elena Khachaturiants; Maria Krasnova; Lidia Guntupova; Svetlana Safonova
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

9.  Failure of isoniazid chemoprophylaxis during infliximab therapy.

Authors:  Manuel L Fernández-Guerrero; Jaime Esteban; Carlos Acebes; Miguel Górgolas
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

10.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.